Zoryl MP 2 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (1000mg), and Pioglitazone (15mg), formulated to provide sustained release for improved glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which improves insulin sensitivity in adipose tissue, muscle, and the liver. The sustained-release formulation ensures gradual drug release, promoting better patient compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Zoryl MP 2 Forte is indicated for patients inadequately controlled on diet, exercise, and monotherapy, offering a multifaceted approach to glycemic management by targeting multiple pathophysiological defects of type 2 diabetes. It should be used under medical supervision with regular monitoring of blood glucose levels, renal and hepatic function. Caution is advised in patients with contraindications such as severe renal impairment, hepatic dysfunction, or a history of lactic acidosis. This combination therapy aims to achieve optimal glycemic control while reducing the risk of diabetes-related complications.